Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleOriginal Research

Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Kristina Callis Duffin, Dafna D. Gladman, Niti Goel, Alice B. Gottlieb, Oliver FitzGerald and Lynne V. McFarland
The Journal of Rheumatology June 2022, 49 (6 Suppl 1) 1-3; DOI: https://doi.org/10.3899/jrheum.211317
Kristina Callis Duffin
1K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kristina Callis Duffin
  • For correspondence: Kristina.callis@hsc.utah.edu
Dafna D. Gladman
2D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dafna D. Gladman
Niti Goel
3N. Goel, MD, Patient Research Partner, Chief Medical Officer, Abcuro Inc., and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niti Goel
Alice B. Gottlieb
4A.B. Gottlieb, MD, PhD, Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and co-chair GRAPPA Publication Committee, New York, New York, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alice B. Gottlieb
Oliver FitzGerald
5O. FitzGerald, MD, FRCPI, FRCP, Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oliver FitzGerald
Lynne V. McFarland
6L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lynne V. McFarland
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its annual meeting in 2021 in an online format due to travel restrictions during the ongoing COVID-19 (coronavirus disease 2019) pandemic. The virtual meeting was attended by rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patient research partners. Similar to previous years, GRAPPA’s annual meeting focused on the 3 overlapping missions of education, research, and clinical care of psoriatic disease (PsD). The virtual meeting allowed a variety of different types of sessions to be held, including the trainee symposium, keynote lectures, interactive sessions (5 Meet the Experts sessions, a debate on first-line therapy, and 5 guided poster sessions), 4 workshops (trainee workshop focusing on the diagnosis of PsD, ultrasound, magnetic resonance imaging, and the International Dermatology Outcome Measures group), updates on a variety of research topics (research findings from the 2020 GRAPPA research grant awardees, 3 basic science talks, Outcome Measures in Rheumatology [OMERACT] Working Group efforts, and Collaborative Research Network progress), current “hot topics” (use of Janus kinase inhibitors, promoting diversity and inclusion in PsD, progress on the updated GRAPPA treatment recommendations, and the introduction of the Young GRAPPA member group), and the presentation of four 2021 GRAPPA grant awardees and election results. In this prologue, we introduce the papers that summarize this meeting.

Key Indexing Terms:
  • dermatology
  • GRAPPA
  • OMERACT
  • outcome measures
  • psoriasis
  • psoriatic arthritis

The 2021 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held over 3 days (July 8–10, 2021) on a web-based platform due to ongoing safety concerns and travel restrictions related to the coronavirus disease 2019 (COVID-19) pandemic. The virtual format allowed greater access for our international membership, which currently includes over 986 members composed primarily of rheumatologists and dermatologists (n = 763), clinicians from other specialties (n = 77), representatives of biopharmaceutical companies (n = 119), and patient research partners (n = 27). The online format was a mix of recorded content and live panel discussions with audience participation using the chat feature. Reports of previous annual meetings have been published elsewhere.1–12

As is customary, the meeting kicked off with the GRAPPA trainee symposium. This session consisted of 5 presentations by rheumatology and dermatology trainees and included the following topics: prediction of cardiovascular events in psoriatic disease (PsD), correlation between spine abnormalities and clinical findings, biomechanical stress as a trigger for psoriatic arthritis (PsA), differences in DNA methylation among twins with PsD, and critical proteins associated with induction of PsD. In addition, 22 posters were presented at 5 discussion sessions.13

As with the 2020 meeting, we held a COVID-19 update session, this year focusing on COVID-19 diagnostic testing and vaccine development.14 Current published guidelines, including recommendations on COVID-19 testing and vaccine response in patients receiving immunomodulating/immunosuppressive therapies, were presented then followed by a panel discussion.

Also returning this year was the debate, covering the question: In the treatment of patients with psoriasis (PsO) or PsA, should interleulkin (IL)-17 or IL-23 inhibitors be used before tumor necrosis factor inhibitors? Two dermatologists and 2 rheumatologists engaged in a lively discussion on this topic.15

The “hot topics” sessions included 2 talks covering the dermatologist’s and rheumatologist’s perspectives on safety considerations of Janus kinase inhibitors (JAKi) in PsDs16 and a program focusing on diversity, equity, and inclusion, highlighting known healthcare disparities and potential solutions.17

The final plenary session covered the 2021 GRAPPA treatment recommendations update. Each of the treatment domain groups summarized their systematic literature reviews and recommendations. Overarching principles and summary evidence tables, including results from a GRAPPA membership survey to assess levels of agreement, were presented and discussed.18

Five Meet the Experts sessions, featuring 9 GRAPPA faculty members, were conducted to allow informal interaction between faculty and meeting participants.19 Topics included the future of GRAPPA, benefits of a GRAPPA copresidency, and ideas to encourage more involvement by dermatologists; pustular psoriasis and SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteomyelitis) syndrome; JAKi for treatment of PsA; topical agents for treatment of PsO; a comparison of axial PsA and axial spondyloarthritis (axSpA); and composite measures in PsA.

Concurrent to the Meet the Experts sessions, the inaugural meeting of the Young GRAPPA group was held. Young GRAPPA was formed in 2021 to provide an early career membership option to improve the inclusion of and support for young researchers and physicians beginning their careers. The initial organizational framework and different components and aims of this group were discussed20 and a link to the GRAPPA website was provided (see GRAPPA Early Career Membership under the Membership tab at https://grappa.memberclicks.net).

Four workshops were held during the meeting. The GRAPPA ultrasound committee held a workshop to cover 3 topics: (1) the Diagnostic Ultrasound Enthesitis Tool (DUET) project; (2) a data-driven approach for scoring systems to distinguish PsA from non-PsA; and (3) the usefulness of sonography of the hands and detection of inflammatory lesions associated with PsA.21 The magnetic resonance imaging (MRI) working group gave presentations on what constitutes a positive MRI for clinical trial recruitment of individuals with axial involvement, and with peripheral involvement in PsA.22 The International Dermatology Outcome Measures workshop covered their progress, including the development of a 7-item treatment satisfaction questionnaire specifically for dermatological conditions, and work on implementing a screening tool for patients with PsO in clinical trials.23 The fourth workshop focused on challenges in the diagnosis and assessment of cutaneous PsO and PsA, differential diagnosis, diagnostic errors and pitfalls, patient-reported outcomes and composite measures in the assessment of PsA, and the patient perspective on diagnosis and assessment.24

Several sessions were devoted to research, including 3 basic science sessions and reports from the GRAPPA–Outcome Measures in Rheumatology (OMERACT) Working Group and the Collaborative Research Network (CRN). The basic science sessions included talks on serum protein biomarkers in PsA,25 recent findings on CD4+ production of IL-17A, and the complex role of the intestinal microbiome in PsA and how microbiome profiles may be useful to predict treatment responses.26 The GRAPPA-OMERACT group presented an update on the domain of structural damage and discussed the steps taken to assess the domain match and feasibility of plain radiographic instruments in the assessment of structural damage in PsA.27 The CRN session addressed novel technological approaches to address unmet needs in PsO and challenges in dealing with big data analysis.28 The research sessions concluded with the 2019 and 2020 research grant coawardees presenting their research projects and preliminary results.29

The close of the meeting included our inauguration ceremony for new leadership and election results. Dr. April Armstrong, a dermatologist from Los Angeles, California, USA, and Dr. Oliver FitzGerald, a rheumatologist from Dublin, Ireland, will be sharing the job as first-ever copresidents to provide equal representation for dermatology and rheumatology. Revisions of the bylaws, election results for the steering committee, and research awards were presented.

Overall, the meeting attendance was excellent, with over 440 registered and over 270 attendees. Of those responding to our meeting survey (n = 74), 94.5% gave the event an overall rating of excellent or very good. Of the respondents, 72% would prefer a hybrid format for future events. It is our hope that we will be able to hold our 2022 annual meeting as a live or hybrid event in Brooklyn, New York, USA.

ACKNOWLEDGMENT

Special thanks go to Sharon Andrews, Executive Director of GRAPPA; Janine Kowack; and to International Medical Press/Nucleus Global for their tireless and collaborative efforts to produce this meeting.

Footnotes

  • As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.

  • Source of support to enable these meetings was provided in 2020 by AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB, BMS, Gilead, Boehringer Ingelheim, and Sun Pharma. In addition, our Innovation Partner in 2020 was Nordic Bioscience.

  • KCD reports the following conflicts: grants/investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim; speaker’s bureau for Novartis (nonpromotional only); consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, BMS, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, Boehringer Ingelheim. OF received research grants and/or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. DDG reports grants and/or consulting fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. NG is a stockholder at UCB. ABG received honoraria as an advisory board member; is a consultant for AnaptsysBio, Avotres Therapeutics, Boehringer Ingelheim, BMS, GSK, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB, Dermavant, and Xbiotech; and received research/educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, and Sun Pharma. LVM declares no conflicts of interest.

  • This paper does not require institutional review board approval.

  • Accepted for publication December 7, 2021.
  • Copyright © 2022 by The Journal of Rheumatology

References

  1. 1.↵
    1. Mease PJ,
    2. Gladman DD
    . Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2011;38:522-5.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Mease PJ,
    2. Gladman DD
    . Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2012;39:391-3.
    OpenUrlAbstract/FREE Full Text
  3. 3.
    1. Mease PJ,
    2. Gladman DD
    . Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2012;39:2181-3.
    OpenUrlAbstract/FREE Full Text
  4. 4.
    1. Mease PJ,
    2. Boehncke WH,
    3. Gladman DD
    . Prologue: 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2013;40:1407-9.
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. Boehncke WH,
    2. Gladman DD
    . Prologue: 2013 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2014;41:1194-6.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Boehncke WH,
    2. Gladman DD
    . Prologue: 2014 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2015;42:1011-13.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Boehncke WH,
    2. Gladman DD,
    3. Helliwell PS
    . Prologue: 2015 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2016;43:949-51.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Helliwell PS,
    2. Gladman DD,
    3. Gottlieb AB
    . Prologue: 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2017;44:658-60.
    OpenUrlAbstract/FREE Full Text
  9. 9.
    1. Helliwell PS,
    2. Gladman DD,
    3. Gottlieb AB
    . Prologue: 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl 2018;94:1-3.
    OpenUrl
  10. 10.
    1. Callis Duffin K,
    2. Gladman DD,
    3. Gottlieb AB,
    4. Goel N
    . Prologue: 2018 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl 2019;95:1-3.
    OpenUrl
  11. 11.
    1. Callis Duffin K,
    2. Gladman DD,
    3. Goel N,
    4. Gottlieb AB
    . Prologue: 2019 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl 2020;96:1-3.
    OpenUrl
  12. 12.↵
    1. Callis Duffin K,
    2. Gottlieb AB,
    3. O’Sullivan D,
    4. Gladman DD,
    5. McFarland LV
    . Prologue: 2020 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl 2021;97:1-3.
    OpenUrl
  13. 13.↵
    1. Armstrong AW,
    2. Reddy RM,
    3. Colaco K, et al
    . 2021 GRAPPA trainee symposium: a summary of oral and poster presentations. J Rheumatol 2022;49 Suppl 1:4-9.
    OpenUrl
  14. 14.↵
    1. Mease PJ,
    2. Winthrop K,
    3. Olsder W,
    4. Curtis J
    . COVID-19 update for the GRAPPA 2021 annual meeting: focus on COVID-19 vaccination. J Rheumatol 2022;49 Suppl 1:10-12.
    OpenUrl
  15. 15.↵
    1. Jadon DR,
    2. Kavanaugh A,
    3. Leung YY
    . Clinical controversies in psoriatic disease: the use of interleukin 17 inhibitor (IL-17i)/IL-23i versus TNFi as first-line advanced therapy in psoriatic arthritis. J Rheumatol 2022;49 Suppl 1:26-31.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Nash P
    . Janus kinase inhibitors: safety in patients with psoriatic arthritis. J Rheumatol 2022;49 Suppl 1:44-7.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Takeshita J,
    2. Chau J,
    3. Callis Duffin K,
    4. Goel N
    . Promoting diversity, equity, and inclusion for psoriatic diseases. J Rheumatol 2022;49 Suppl 1:48-51.
    OpenUrl
  18. 18.↵
    1. Coates LC,
    2. Corp N,
    3. Vvn der Windt DA,
    4. O’Sullivan D,
    5. Soriano ER,
    6. Kavanaugh A
    . GRAPPA treatment recommendations: 2021 update. J Rheumatol 2022;49 Suppl 1:52-4.
    OpenUrl
  19. 19.↵
    1. Armstrong AW,
    2. Reddy RM,
    3. FitzGerald O, et al
    . 2021 GRAPPA Meet the Experts: a summary of presentations. J Rheumatol 2022;49 Suppl 1:32-6.
    OpenUrl
  20. 20.↵
    1. van Mens L,
    2. Ayan G,
    3. Coates LC, et al
    . Young-GRAPPA at the annual GRAPPA meeting: presentation of a new group within GRAPPA and its vision. J Rheumatol 2022;49 Suppl 1:37-9.
    OpenUrl
  21. 21.↵
    1. Aydin SZ,
    2. Eder L,
    3. Kaeley GS
    . Toward a sonographic composite index for diagnosis in psoriatic arthritis: highlights from the GRAPPA ultrasound workshop. J Rheumatol 2022;49 Suppl 1:67-71.
    OpenUrl
  22. 22.↵
    1. Maksymowych WP,
    2. Østergaard M
    . What constitutes a positive MRI for clinical trial recruitment of psoriatic arthritis patients with axial involvement? J Rheumatol 2022;49 Suppl 1:72-4.
    OpenUrl
  23. 23.↵
    1. Yousif J,
    2. Merola JF,
    3. Perez-Chada LM, et al
    . Report of the skin research working group from the GRAPPA 2021 annual meeting. J Rheumatol 2022;49 Suppl 1:40-3.
    OpenUrl
  24. 24.↵
    1. Ogdie A,
    2. Lindsay CA,
    3. Mease PJ,
    4. Callis Duffin K,
    5. Rosen CF,
    6. Siebert S
    . Challenges in the diagnosis and assessment of psoriatic arthritis J Rheumatol 2022;49 Suppl 1:64-6.
    OpenUrl
  25. 25.↵
    1. Waddington JC,
    2. Coleman O,
    3. Mease PJ, et al
    . Basic science session 1. Biomarkers for psoriatic arthritis treatment response and joint damage progression: an update on 2 Industry-GRAPPA projects. J Rheumatol 2022;49 Suppl 1:13-15.
    OpenUrl
  26. 26.↵
    1. Lubberts E,
    2. Scher JU,
    3. FitzGerald O
    . Basic science session 2. Recent advances in our understanding of psoriatic arthritis pathogenesis. J Rheumatol 2022;49 Suppl 1:16-19.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Antony A,
    2. Holland R,
    3. Matthew AJ, et al
    . Plain radiographic instruments for structural damage in peripheral joints in psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J Rheumatol 2022;49 Suppl 1:20-5.
    OpenUrl
  28. 28.↵
    1. Stober C,
    2. McInnes IB,
    3. Raychaudhuri S, et al
    . Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) meeting. J Rheumatol 2022;49 Suppl 1:57-63.
    OpenUrl
  29. 29.↵
    1. Castillo RL,
    2. Yan D,
    3. Ashhurst AS, et al
    . GRAPPA 2020 research award recipients. J Rheumatol 2022;49 Suppl 1:55-6.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 49, Issue 6 Suppl 1
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Kristina Callis Duffin, Dafna D. Gladman, Niti Goel, Alice B. Gottlieb, Oliver FitzGerald, Lynne V. McFarland
The Journal of Rheumatology Jun 2022, 49 (6 Suppl 1) 1-3; DOI: 10.3899/jrheum.211317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Kristina Callis Duffin, Dafna D. Gladman, Niti Goel, Alice B. Gottlieb, Oliver FitzGerald, Lynne V. McFarland
The Journal of Rheumatology Jun 2022, 49 (6 Suppl 1) 1-3; DOI: 10.3899/jrheum.211317
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • ACKNOWLEDGMENT
    • Footnotes
    • References
  • Info & Metrics
  • References
  • PDF

Keywords

DERMATOLOGY
GRAPPA
OMERACT
OUTCOME MEASURES
PSORIASIS
PSORIATIC ARTHRITIS

Related Articles

Cited By...

More in this TOC Section

  • Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study
  • GRAPPA 2019 Research Recipient Awards Report
  • The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop
Show more Original Research

Similar Articles

Keywords

  • dermatology
  • GRAPPA
  • OMERACT
  • OUTCOME MEASURES
  • psoriasis
  • psoriatic arthritis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire